Is Bristol-Myers Squibb (BMY) overvalued or fairly valued?

MarketChacha shows Bristol-Myers Squibb's valuation in context — a forward P/E of about 9.7, a price-to-book of about 6.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb last traded at $60.16 (-1.0% on the day), as of 7/20/2026 — a delayed quote shown for education, not investment advice.

Bristol-Myers Squibb

BMY · NYSE · Pharma · United States

$60.16-1.0%

Delayed · as reported by Yahoo Finance · as of Jul 20, 2026, 8:00 PM

Snapshot

TickerBMY

ExchangeNYSE

SectorPharma

IndustryDrug Manufacturers - General

CountryUnited States

Employees32,500

HeadquartersPrinceton, United States

Market cap$123.1B

P/B6.1

Volume8.12M

Websitewww.bms.com

Filings tracked0

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.1%
Institutions83.8%
Public & other16.1%

3,246 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.8.41%
Vanguard Capital Management LLC6.48%
State Street Corporation4.83%
JPMORGAN CHASE & CO4.53%
Charles Schwab Investment Management, Inc.2.99%
Geode Capital Management, LLC2.71%
Vanguard Portfolio Management LLC2.26%
Bank of America Corporation1.60%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $12.0B · EPS 1.61

Est. earnings growth -1.1%

Next fiscal year

Rev $46.4B · EPS 6.20

Est. earnings growth -2.3%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$42.5252-wk range$62.89

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about BMY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.